-
Published 6/30/2026
Dirnberger F, Patel S, Boyne DJ, Lan Z, Uyei J, Wang J, Cho S, DeCosta L, Bridges IM, Tapan U. Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer. Adv Ther. 2026 Jun 30. PMID: 42377743.
-
Published 6/18/2026
Ferri GM, Murphy JF, Oza A, Bulteel AJB, Abbasi W, Anderson R, Dinc MT, Gaufberg E, Cengiz K, Sontha S, Weinberg J, Kurpaska P, Mangala YO, Kulke M, Tapan U. Safety of immune checkpoint inhibitors in a diverse patient population: a single-institution experience. Ecancermedicalscience. 2026; 20:2150. PMID: 42453165.
-
Published 5/20/2026
Hill NR, Crosbie A, Szymialis R, Botros A, Zhang Y, Tapan U. Impact of social determinants of health on treatment patterns and outcomes in metastatic non-small cell lung cancer. J Oncol Pharm Pract. 2026 May 20; 10781552261449764. PMID: 42159393.
-
Published 3/10/2026
Kim JY, Dirks A, Ford RM, Pai L, Ludwig C, Tapan U. How exclusion criteria can hinder eligibility for lung cancer studies among different racial and ethnic groups. PLOS Digit Health. 2026 Mar; 5(3):e0001262. PMID: 41805924.
-
Published 1/24/2026
Martinez CB, Bhatt S, Battaglini J, Beckett A, Tapan U. Lung Cancer in the Incarcerated Population: A Narrative Review. Curr Oncol Rep. 2026 Jan 24; 28(1):2. PMID: 41579227.